The aim of the competition is to highlight top tips for pet owners and the benefits of building a den to help calm and reassure dogs during the fireworks festivities.
Practices that want to take part in the in the competition need to post pictures of their dens and waiting rooms on the Ceva Animal Health Facebook page in October. The winning practice will receive a £200 voucher and there are 10 runner up prizes of luxury chocolate hampers.
Abigail King, behaviour product manager at Ceva Animal Health, said: "Our hugely popular fireworks display competition encourages veterinary practices to create eye-catching and imaginative displays that help educate pet owners on what can be done at home to help calm and reassure pets with firework fears."
Ceva has a range of marketing materials for veterinary practices to use in the competition, including waiting room materials.
For further information, contact your Ceva territory manager.
Discospondylitis describes the infection of an intervertebral disc and its adjacent cartilaginous end plates and vertebral bodies.
It is commonly bacterial or fungal in origin.
The disease can be challenging to diagnose as signs are variable and sometimes vague.
For the research, neurology specialists retrospectively examined cases which presented at multiple referral sites that have furthered the understanding, clinical and imaging features of discospondylitis.
To date MRI has been the imaging modality of choice, with consistent CT imaging features of discospondylitis in dogs and cats not previously reported in detail.
However with the increased availability of CT in clinical practice, the research set out to examine CT features that could support a diagnosis of discospondylitis.
Discospondylitis in cats is uncommon, and very little research had been undertaken in this area. This research group therefore reported clinical presentation and imaging data about a population of cats, to support the future diagnosis of these cases.
During the three studies*, the researchers found that:
The studies
VetSurgeon member Shailen Jasani MA VetMB MRCVS DipACVECC has launched the Ralph site (theralphsite.com), a website offering support and advice to those coping with pet bereavement.
The site contains forums, downloadable advice sheets, a directory of crematoria and cemeteries, and offers owners the ability to create a memorial for their pet.
The Ralph site was named after Shailen's own cat, which died after a car accident in 2010. Shailen funded the setup of the site, and it is a not-for-proft.
The product was one of eight NSAIDS that had been suspended following a European ruling that an excipient, diethanolamine, may pose a risk to human health.
Allevinix is licensed for both intravenous (I/V) and intramuscular (I/M) administration over one to three days in cattle. It has a dose rate of 4ml per 100kg liveweight in cattle, and milk withdrawal times of 24 hours after I/V injection and 36 hours after I/M injection.
Ceva says Allevinix reaches peak plasma levels (CMax) approximately 30 minutes following I/M injection. It is available in 100ml and 250ml vials.
Peter Keyte, ruminant business unit manager at Ceva Animal Health, said: "Allevinix is the only flunixin licensed for both intramuscular and intravenous administration in cattle and provides both vets and farmers with a cost-effective, fast-acting and versatile NSAID that is a useful addition to the range of NSAID options available."
For more information, contact your Ceva account manager, email cevauk@ceva.com or call the ruminant marketing department at Ceva on 01494 781510.
Being an intranasal vaccine, Bovalto Respi IN triggers mucosal immunity in the nasal passages and throat area. It can be delivered from 10 days of age without the need for a booster and provides immunity for 12 weeks, from 10 days after vaccination.
Boehringer says it has also been shown to be effective in the face of MDA (maternally derived antibodies).
The new bottle now has a wider neck, which apparently makes for a better fit with the accompanying Respisafe applicator and nozzle.
Brand manager Matt Yarnall said: "The Respisafe applicator ensures that vaccination is a comfortable process for both farmer and calf and the improved fit will make the job even easier.
"With an intranasal vaccine, it is important that the vaccine droplets coat the mucosa of the nasal passages, where they can begin to work. If they are too big, then the vaccine can run out of the nose, and if too small then the droplets are carried into the lungs and are wasted. The Respisafe system ensures that the optimum size of droplet is administered to the right place in an efficient and easy way.”
Bovalto Respi Intranasal protects against the two main respiratory viruses – RSV and PI3, and during its development it was tested against current strains, that are associated with causing disease in cattle1.
Stock of the new bottles will start to enter circulation with vets from mid-July, with an expectation that the existing version will still be in circulation until early in the new year.
Reference
Mr Wood was convicted of three offences which involved the download of 38 videos and 13 indecent images of children, at Portsmouth Magistrates’ Court in December 2017.
In January 2018, he was sentenced to a three-year Community Sentence for each offence, to run concurrently, and was made subject to a five-year Sexual Harm Prevention Order.
He was also fined £1,000 and ordered to pay costs of £340 and a victim surcharge of £85.
Mr Wood was also placed on the barring list by the Disclosure and Barring Service and required to register with the police pursuant to the Sexual Offences Act 2003 for a period of five years.
Mr Wood appeared before the Disciplinary Committee, admitted his conviction and accepted that it rendered him unfit to practise veterinary surgery.
In determining the sanction, the Committee says it took into account a number of mitigating factors: his conviction involved no actual harm or risk of harm to an animal; there was no financial gain; he had engaged in open and frank admissions at an early stage; he was experiencing mental ill-health at the time of the offence; he had taken subsequent steps to avoid a repetition of such behaviour; there had been a significant lapse of time since the incident; and he showed insight into the harm caused by his offence.
The Committee also considered that the purpose of a sanction is not to punish, but to protect the welfare of animals, as well as maintain public confidence in the profession and declare and uphold proper standards of conduct. On consideration of the appropriate sanction, the Committee decided that postponement of judgement was not appropriate, and that taking no action was not an option.
The Committee then considered whether a reprimand or warning was appropriate, but they considered that would not match the gravity of the offence – a period of suspension would also mean Mr Wood would automatically return to the Register after the period of time without the College being able to review his fitness to practise, rendering it an inappropriate sanction. The Committee therefore determined that the removal of Mr Wood from the RCVS Register was the only way to protect the wider public interest and maintain confidence in the profession.
Ian Green, chairing the Committee and speaking on its behalf, said: "The Committee has not taken this decision lightly, and, lest it be misinterpreted, it has not taken it in order to satisfy any notional public demand for blame and punishment.
"It has taken the decision because in its perception, the reputation of the profession had to be at the forefront of its thinking and ultimately it was more important than the interests of the Respondent.
"The decision is not simply based on the fact that these offences were of a sexual nature but because they were repeated frequently over a significant period of time, and at the time, the Respondent knew on his own admission that what he was doing was wrong.
"Accordingly, the Committee had decided that removal from the Register is appropriate and proportionate in this case. The Committee will direct the Registrar to remove the Respondent’s name from the Register forthwith."
Mr Wood has 28 days to appeal the Committee’s decision after which, if no appeal is received, the Committee’s judgment takes effect.
Amflee Combo, a POM, is being launched by a newcomer to the UK market, a Slovenian company called Krka (pronounced kirka). The company says it plans to introduce a vast range of small and production animal products onto the UK market in the next few years.
Killian Gaffney, Head of sales and marketing at Krka, says the company intends to support UK veterinary surgeons by offering high quality products and by building business relationships that will help protect veterinary incomes, at the same time as offering good value to their customers.
Killian said: "Amflee Combo has some unique features that we believe will set it apart from the competition. We know the combination of the two active ingredients in Amflee Combo is very effective for the treatment of fleas, ticks and biting lice and as part of a treatment strategy for flea allergy dermatitis in dogs and cats. S-methoprene is also effective against flea eggs and larvae in the environment.
"However, these ingredients can be susceptible to degradation when subjected to light and moisture, which is why each Amflee Combo pipette comes in its own special foil wrapper. The pipettes have also been designed for convenience of use, since we know that only 22% of owners apply spot-ons correctly1."
A range of product and client literature to support the use of Amflee Combo is available by calling 01753 722 150.
Amflee Combo is available in a variety of packs for cats and different sized dogs, containing either three or six pipettes. The recommended treatment is one pipette every four weeks.
Further information about Amflee Combo or Krka is available at www.krka.co.uk
1 El veterinario ante el cambio climatico Argos 107, 2010.
The re-categorisation means veterinary practices can sell the topical parasiticides to ‘walk-in clients’ without the need of a prescription.
Andrew Fullerton, veterinary surgeon and product manager at Ceva Animal Health, said: “The new NFA-VPS category for Vectra 3D spot-on solution for dogs and Vectra Felis 423mg/42.3mg spot-on solution for cats provides veterinary practices with greater flexibility to sell easy-to-use, fast and effective parasite prevention and treatment without a prescription."
For more information, contact your Ceva Animal Health account manager or email cevauk@ceva.com.
The authors say that the prognosis for dogs with stage II Kiupel high-grade cutaneous mast cell tumours has historically been considered poor.
However, the removal of metastatic regional lymph nodes in more recent research has been associated with a better outcome in canine cutaneous mast cell tumours.
For this study1, dogs with a histological diagnosis of overt lymph node metastasis that underwent lymphadenectomy (n = 31) were compared with those with a cytological diagnosis of regional lymph node metastasis, that did not undergo excision (n 18).
The study was a multi-institutional retrospective cohort study, using electronic medical records from four European institutions to identify dogs for inclusion.
The study found that dogs with Kiupel high-grade cutaneous mast cell tumours undergoing lymphadenectomy of HN3 lymph nodes as part of their primary surgery in addition to adjuvant medical treatment had a significant improvement in time to progression and survival time compared with those dogs not undergoing the procedure.
Lack of lymphadenectomy was the only variable significantly associated with a higher risk of nodal progression.
Dogs underwent lymphadenectomy of one peripheral lymph node in most cases.
The authors says that a higher number of lymph nodes or the removal of intracavitary lymph nodes might be associated with an increased incidence of postoperative morbidity.
They add that the findings warrant further exploration of the effect of surgical extirpation of metastatic sentinel lymph nodes and the number of lymph nodes removed on outcome in dogs with Kiupel high-grade cutaneous mast cell tumours.
Nicola Di Girolamo, Editor of JSAP said: “It is really encouraging to see collaborations from multiple institutions like the study presented here.
"Including multiple institutions in a retrospective cohort study, does not only ensure a higher sample size, but also ensure a higher generalisability of the results.
"Meaning that it is more likely that the differences observed in this study are also going to be observed at different practices and with different clinicians.”
https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13525
The tool is available to all practices, free of charge.
The downloadable and printable guide chart, which has been created by a number of specialists, will help veterinary surgeons, nurses and receptionists to identify urgent, potentially urgent, non-urgent and delayable cases to help limited veterinary resources be used to best efficiency without compromise to animal health or welfare.
The chart, which can be printed and put on a practice wall or referred to as a webpage via a mobile phone or tablet, has a number of supporting resources produced by the same specialists.
Sue Paterson, BSAVA President, said: “During these exceptional and worrying times veterinary surgeons need as much practical help and support as possible.
"We are hugely grateful for the indefatigable support of an enthusiastic group of volunteers who have rapidly produced this triage tool, which we are now able to share. It should enable patient queries to be processed, reliably and efficiently, allowing for emergency patients to be seen as a matter of urgency, within the current government and RCVS guidelines."
The triage tool is free to download and share: https://www.bsava.com/TriageTool
BSAVA is working on a number of other initiatives to support veterinary professionals during the current crisis, including new guidance on obtaining consent remotely for veterinary treatment. for more information, visit: https://www.bsava.com/adviceforCOVID19
Intervet/Schering-Plough Animal Health is to launch CICADA-Live, the second phase of its national initiative to monitor the awareness and regional prevalence of important diseases in cats, dogs and rabbits.
First launched in 2007 as a quarterly survey, the ground-breaking CICADA-Live project has now been developed to offer up-to-the minute data on infectious companion animal disease reports that can be updated and accessed by vet practices around the clock. The new scheme is now able to provide a real-time overview of companion animal infectious diseases being diagnosed in UK veterinary practices.
CICADA-Live is focusing on more than a dozen key infectious diseases of dogs, cats and rabbits. They include canine parvovirus, infectious canine hepatitis, canine distemper, leptospirosis, kennel cough, angiostrongylosis. For cats, CICADA-Live will monitor feline panleucopaenia, cat flu, feline leukaemia virus infections. For rabbits the focus will be on myxomatosis, rabbit viral haemorrhagic disease, E.cuniculi, and fly strike.
The service is officially launched on 1st June to coincide with Intervet/Schering-Plough Animal Health's National Vaccination Month 2009, and is open to all first-opinion UK companion animal veterinary practices.
The system's developer, John Helps, Veterinary Manager at Intervet/Schering-Plough Animal Health said: "Whereas our first edition of CICADA was useful in providing benchmarks so that seasonal and long term trends could be identified and communicated to both vets and pet owners, the further potential of a live on-line database is enormous in raising awareness of current pet disease risks to the public."
According to the company, there has been a lack of knowledge regarding the local and national incidence of small animal infectious diseases in the UK, and those sporadic reports that do occur are typically anecdotal and can prove hard to substantiate. It is feared that the lack of co-ordinated good quality information has potentially lead to pet owners being lulled into a false sense of security by a low awareness of disease risks.
John added: "Lack of data on the incidence and prevalence of even the most common infectious diseases has been an important issue faced by small animal practices reducing their ability to highlight these risks. A staggering lack of owner awareness to infectious disease threats in turn contributes to complacency among pet owners.
"Evidence suggests that some infectious diseases, such as parvovirus, may be on the increase in some areas and there continues to be a concern regarding the number of animals that remain unvaccinated.
"Not only will Cicada-Live provide the means for improving a gap in our collective knowledge but it will also prove invaluable in the promotion of good preventative healthcare.
"We have long believed that better epidemiological surveillance would an important tool in understanding trends in small animal infectious disease and with CICADA-Live, for the first time we have a tool to give us a better appreciation of what first opinion practices are currently seeing."
The CICADA-Live website, http://www.cicadasurvey.co.uk/, is simple to access and update. Registrations are limited to one per practice branch. A straightforward one-page survey format minimises the time investment, with no strict requirement to review written case records.
Once signed in, participating practices will be asked to complete the survey once every 6 months in order to grant continued access to maps and tables showing recent reports. In addition practices can set up e-mail alerts to give notification should disease reports be received in their area.
For further information about CICADA-Live from Intervet please contact Intervet /Schering-Plough Animal Health's Veterinary Support Group on 01908 685685. Or contact John.
Willows, the Solihull-based multidisciplinary referral centre, has announced that it has acquired The Veterinary Cardiorespiratory Centre, the renowned referral service run by Mike Martin MRCVS, RCVS Specialist in Veterinary Cardiology (pictured right).
Mike, together with Chris Linney and their team will shortly be moving half-an-hour up the road to join the team at Willows.
The company says that the move will offer a number of benefits to referring practitioners. Chief amongst these is the speed with which an accurate diagnosis can be made and treatment given, both as a result of having RCVS Specialists in neurology, imaging, medicine, soft tissue surgery (and now cardiology) under one roof and because of the state-of-the-art equipment at their disposal, including CT, MRI and digital fluoroscopy.
Lynne Hill, CEO, Willows Group said: ”I’m thrilled that Mike, Chris and their team are joining us at Willows. I have always held Mike in the highest regard and this is a tremendous opportunity for the practice to provide a truly collaborative ‘one-stop-shop’ for both clients and referring veterinary practices”.
Mike said: “I’m really looking forward to working at Willows Referral Service and being part of a multidisciplinary team. It's a logical move to provide Willows with the missing discipline of cardiology and I'm delighted Lynne Hill has allowed us to fulfil that role. There has been an increasing number of referrals between the two centres due to the complexity of cases - now that will be all under one roof and we can manage these much more effectively and offer the best service to our clients and their patients.”
For more information, visit www.willows.uk.net
The company says this means that using Solacyl as an alternative to antibiotics could reduce overall antibiotic use by 4.4 tonnes a year.
The research was carried out by dairy veterinary consultant Owen Atkinson BVSc DHCP MRCVS, an RCVS recognised specialist in cattle health and production, at three English calf rearing units between November 2017 and May 2018. It involved four groups of beef calves from different dairy farms.
The 258 calves were given Solacyl (sodium salicylate) in-feed on the five days immediately upon arrival at the units (a high-risk period for animals to contract bovine respiratory disease).
According to Dechra, the use of Solacyl resulted in a reduction in antibiotic use of between 16% and 73% (based on doses), depending on the farm. Across all groups, the reduction was 43%.
Dechra says that neither the health of the calves nor the profitability of the rearing operations were compromised.
Owen Atkinson said: "I was involved in analysing the data and the data showed that there was no significant difference in growth rates or in mortality or in days to reach a target weight in the calves that had Solacyl, compared to previous batches of calves that had followed a prophylactic antibiotic protocol.
"I think this is an ideal protocol for those farmers who are competent, who are able to spot early pneumonia symptoms and are prepared to perhaps treat a slightly higher proportion of calves than they would otherwise have treated. They can now do that with higher confidence that their results should be as good as if they had used prophylactic antibiotics."
Dechra Farm Animal Veterinary Adviser Alana McGlade BVmedsci (hons) BVM BVS MRCVS added: "Sodium salicylate has the same fever-controlling, pain-managing and inflammation-reducing benefits in livestock as aspirin can have in humans.
"It can be administered conveniently to groups of animals, which means it can be given prior to known stress points in animals’ lives. This can be continued through and after those events, providing a welfare benefit and reducing the risk of a loss of appetite and its resulting effects.
"Solacyl can be administered without the supervision of a vet and that makes it a cost-effective and practical solution for farmers that can lead to a notable reduction in routine antibiotic use whilst protecting the welfare of a herd."
Dechra has now published a white paper which you can download here: "Enhancing welfare and combating antimicrobial resistance while maintaining productivity on calf units".
The results of the research will be presented at the BCVA Congress in October 2018.
The Government says that contracts have been secured with Brittany Ferries and DFDS to run ferries into and out of Poole, Portsmouth, Plymouth, Immingham and Felixstowe, thereby relieving pressure on the Dover straights.
Critical goods have been identified as those essential for the preservation of human and animal welfare, including all veterinary medicines authorised under the Veterinary Medicines Regulation 2013, including finished and un-finished products, and Active Pharmaceutical Ingredients (for import and export).
Critical goods also include unauthorised medicines permitted for import under the Veterinary Medicines Directorate’s Special Import Scheme (for import only).
Photo: Shutterstock/Peter Hermes Furian
The company says the system uses a combination of image recognition technology, algorithms and cloud-based artificial intelligence to deliver accurate testing results at the time of visit, within 9 minutes in fact, giving veterinary surgeons the ability to diagnose and treat patients quickly, without the need for a second appointment.
Vetscan Imagyst will detect the eggs, cysts, and oocysts of whipworm, hookworm, roundworm, Giardia, and coccidia
Richard Goldstein, DVM, DACVIM, DECVIM-CA, VP Global Diagnostics Medical Affairs at Zoetis, said: "Parasites are a threat throughout the year, making routine monitoring critical to pet health.
“With Vetscan Imagyst, the ability to have accurate, fast results at the point-of-care empowers veterinarians to diagnose and treat in the same visit, increasing compliance and eliminating follow-up appointments and call backs, thus enhancing the overall pet owner experience.”
Vetscan Imagyst will launch in the UK next week. For more information, contact your Zoetis representative or visit at www.vetscanimagyst.com.
Porus One contains renaltec, a selective absorber that absorbs the precursors of uraemic toxins in the cat’s intestine that would normally be removed or regulated by healthy kidneys, so that they may be safely excreted in the cat's faeces.
The product is presented as a powder which can be sprinkled on wet cat food, or given with Add One as a treat.
Dechra says it is well-accepted by cats due to its neutral taste and smell.
Add One is a moist and tasty cat treat developed to encourage cats that prefer dry food to eat Porus One.
It is available in two flavours: creamy salmon and tasty liver.
Add One contains omega-3 and a high moisture content to help support kidney health.
It also contains taurine to support a cat’s eyes and heart.
One box of Porus One contains 30 single-dose sachets, each containing 500mg of renaltec.
One box of Add One contains 30 single-dose 10mg sachets.
https://porus-one.com.
Dechra Veterinary Products has launched Anesketin, an anaesthetic licensed for cats, dogs and horses.
Anesketin contains ketamine 100mg/ml solution for injection and is indicated for induction of anaesthesia. In cats, it can also be used as a sole agent for restraint and minor surgical procedures where muscle relaxation is not required.
Dechra Brand Manager Carol Morgan said: "Anesketin is a versatile product which can be used as a sole agent in cats or in combination with appropriate sedatives and analgesics in cats, dogs and horses for induction and maintenance of anaesthesia.
Anesketin is available in 10 ml vials. The withdrawal period for meat, offal and milk is one day and the product does not require any special storage conditions.
For further information, visit www.dechra.co.uk
Dechra Veterinary Products has launched a 5 ml bottle of Comfortan (methadone), its titratable analgesia for cats and dogs.
The new sized bottle of Comfortan, designed for use with animals in, or about to experience, moderate to severe pain, is now available from veterinary wholesalers.
Dechra Brand Manager Craig Sankey said: “The new 5ml bottle is a great size for practices which would like to introduce Comfortan into their practice protocols, allowing them to do so in a cost-effective way.
“The availability of a smaller bottle will also be a benefit to practices which due to different surgical needs, currently only use Comfortan in a small number of cases. They will then be able to simply and easily trade up to the 10 ml bottle once they start to use Comfortan on more cases.”
The 5 ml has also been introduced in response to demand from branch practices which had been transferring 10ml bottles between sites and for cat-focused practices which use smaller volumes of the product.
Rodney (pictured right) has spent the last 26 years practising in the USA, latterly at the California-based Advanced Veterinary Specialists & Animal Specialty Group.
After growing up in Zimbabwe and graduating from the University of Pretoria in South Africa in 1985, he moved to London, where he became an MRCVS, and thence to the USA.
He undertook a small animal internship at the Animal Medical Centre in Manhattan, before moving to the Ohio State University for his residency in medical oncology in 1989. He achieved Board Certification in medical oncology in 1994 and in radiation oncology in 2000.
Rodney specialises in the application of multi-modality therapy protocols for the treatment of cancer in animals, and has conducted research on the phenomenon of multi-drug resistance, mast cell tumour and oral melanoma.
He said: "Thirty-something years on, I have come back to the UK as a specialist, where I started as a GP. Living in the UK also brings me much closer to my family, which is very important to me.
"Over the years, veterinary practice in the USA has changed significantly, where it has become more corporate and less personal. I enjoy being part of a new group where typically it is much closer, friendlier and more like a family."
Rodney now plans to oversee the development of a comprehensive oncology department to include chemotherapy, surgery, radiation therapy, immune-therapy and molecular targeted therapy.
He said his work at Paragon will focus on educating referring vets and clients about what is possible in the oncology field.
He said: "My job will be about increasing the level of knowledge, both of owners and general practitioners, of how we treat cancer in animals.
"It can be a scary disease and the first door an owner needs to step through, is understanding that treating a pet is very different to treating a human.
"The intention in humans is usually to cure but with pets, it is more about providing a good quality of life for as long as possible.
"There can be a fear of cancer therapy but if you stick to the protocols, it is no different to treating any other chronic incurable diseases. We use the safest methods with an abundance of caution and try to make sure that the treatment is not worse than the disease.
"It’s about internal training too, from reception right up to nurses and interns, looking at what we do and how we do it, to optimize the quality of life of the pet and their owners.
"I would like to see an oncology department that considers the emotional, financial, time and patient concerns of the owners, so they feel their commitment to cancer treatment for their pet is not a commitment to putting their pet or themselves through a difficult time."
The company says the new product has been 10 years in development and uses 'Soft Mist' technology - developed originally for human use by its pharma business - to deliver medication deep into the horse's lungs.
The active ingredient in the Aservo EquiHaler is ciclesonide, a corticosteroid that is activated directly in the lung, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks commonly associated with systemic corticosteroids.
The Aservo EquiHaler does not use a propellant, so it does not contribute to greenhouse gas emissions. Boehringer also highlights that it is made from up to 50% recycled materials. In April, the product was awarded a Red Dot Design Award.
Dr Marc Laemmer, Head of Equine in UK & Ireland said: "It's another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation.
"We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo EquiHaler available. Out team of territory managers and vet advisers will conduct remote meetings with customers to make sure that they have the information and support they require."
The long-awaited Panorama programme about the veterinary profession will air on Thursday 22 July at 9pm on BBC One.
Rumour has it that the programme will cover a range of issues, including the role of unqualified nursing staff in the practice, support for new graduates, over-charging in relation to insurance and regulation of corporate practices.
The RCVS says it expects increased public interest in the regulation of the profession following the programme and is gearing itself up to address any concerns it raises. A statement will be posted on www.rcvs.org.uk immediately following the programme, and the RCVS has said that it will work with the British Veterinary Association and other organisations to ensure that the robust nature of the regulatory system is communicated to the public, from undergraduate degrees through the Professional Development Phase and the Guide to Professional Conduct, to mandatory continuing professional development and the voluntary Practice Standards Scheme and Register for Veterinary Nurses.
In a statement issued today, the RCVS said: "We currently receive around 700 complaints a year - about one every 15 years of a member's practising life. It's a record to be proud of. However, if the programme raises areas of genuine concern, we will do all we can to act on them and we have already made it clear to the BBC that we would expect their support in this."
Zenifel contains synthetic feline facial pheromones which imitate the facial F3 pheromone which has been found to be significantly important when it comes to cats creating areas they feel safe and relaxed in1.
According to the company, Zenifel contains a 48ml vial of the same synthetic F3 feline facial pheromone as the market leader, but, thanks to its own diffusion system and a higher concentration of F3, lasts up to 6 weeks; i.e. 50% longer. This, says Virbac, means that Zenifel is both more economical and more environmentally friendly.
Alongside the launch of the new product, Virbac is offering a practice support pack which includes things you need to create a calm area for feline visitors and promote the benefits of pheromones to pet owners. The company is also running a promotion in which practices could be eligible for a year’s free supply of Zenifel.
For more information, contact your local Virbac Territory Manager.
Freelance Surgical says electrosurgery has yet to take off in the veterinary profession in the way that it has in human surgery because many veterinary surgeons are still unfamiliar with the technology and have concerns about safety.
In fact, the company says, it can make surgery more efficient, faster and safer.
In the new series of videos, Alasdair Hotston Moore covers the background of electrosurgery, an overview of the Gima Diathermy unit and a practical demonstration of how to use the equipment correctly and safely.
Bilitis Hammond, Veterinary Specialist at Freelance Surgical said: “With the GIMA electrocautery units being so popular, we were surprised to find there was very little training on best use available online.
"We wanted to offer some short bitesize videos that show surgeons what this machine can offer so they are using it to its full potential and safely.
"We feel these videos will be a huge asset to everyone in practice. “
https://www.youtube.com/channel/UCfKRtTQ2EA16cP-gfkqSVdA
https://www.freelance-veterinary.co.uk/surgery/electrosurgery
Amir Kashiv faced a charge of being unfit to practise veterinary surgery after twice being found guilty of letting dogs roam freely on public highways or land not owned or controlled by him in Peterborough Magistrates’ Court, once on 20 April 2016 and once on 16 November 2016, and by having repeatedly breached court orders in relation to the same.
Dr Kashiv admitted the convictions, but denied that individually or in any combination they rendered him unit to practise veterinary surgery. This was therefore left to the judgement of the Committee.
In considering whether the convictions rendered Dr Kashiv unfit for practice, the Committee first considered the facts of the convictions.
Dr Kashiv had long taken in house dogs with physical and behavioural problems, at some stages having as many as 30 on his property. In 2014 neighbours became concerned by dogs escaping and noise nuisances, and on 14 November 2014 Dr Kashiv was served by the Police with a Warning Notice, requiring him to install adequate fencing within 28 days.
Four days later he was then served with an Abatement Notice for a Noise Nuisance about the dogs, and on 10 January 2015 he was then served with a Community Protection Notice requiring him to stop his dogs roaming and ensure adequate fencing.
After multiple subsequent escapes Dr Kashiv pleaded guilty of being in breach of the Community Protection Order at the Magistrates’ Court on 20 April 2016, receiving penalties amounting to £5,000 and costs of £6,000, as well as a two year Criminal Behaviour Order requiring him to reduce the number of dogs to no more than five with 28 days, and requiring his dogs to be supervised at all times while they were outside the house.
Two months later one of the dogs was seen outside the property, resulting in another conviction for breach of the Criminal Behaviour Order on 16 November 2016, and Dr Kashiv was fined £250 as well as £250 in costs.
The Committee then considered whether this resulted in Dr Kashiv being unfit to practise veterinary surgery. It considered it a serious matter that a veterinary surgeon should allow himself to be made subject to a Warning Notice, and that, being subject to such a Notice, he should then be found in repeated breach of the Notice and invite prosecution. While the Committee accepts that it is difficult to fence his entire grounds, ten acres in total, the Committee took it as a mark against Dr Kashiv that he failed to address the concerns of the authorities by reducing the number of dogs he housed until he was compelled to do so.
Jane Downes, who was chairing the Committee and speaking on its behalf, said: "The Committee regards this as a case close to borderline. These offences, involving the mismanagement by a veterinary surgeon of his animals and repeated offences demonstrate that Dr Kashiv had a less than adequate insight in 2014 and 2015 into the seriousness of the situation or into the understandable concerns of his neighbours and of the authorities. They are capable of bringing the profession into disrepute so as to undermine public confidence in it.
"But, in the end, The Committee has concluded that Dr Kashiv is not unfit by reason of these convictions to practise as a veterinary surgeon.
"It is apparent from the material before the Committee that Dr Kashiv is a dedicated veterinary surgeon whose life’s work has been devoted to the welfare of small animals and who has gone to extraordinary lengths, at his own expense, to do all that he possibly could to alleviate the suffering of, and rehabilitate, unloved and abandoned and unwell dogs.
"In all the circumstances and in the light of all the evidence the Committee finds that the convictions, whether taken individually or in any combination, do not render Dr Kashiv unfit to practice veterinary surgery."
Tulaven is licensed for the treatment and metaphylaxis of BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis.
Tulaven can also be used to treat Infectious Bovine Keratoconjunctivitis (IBK) associated with Moraxella bovis as well as Porcine Respiratory Disease Complex (PRDC) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica.
Tulaven is also is licensed to treat the early stages of infectious pododermatitis (foot rot) in sheep associated with virulent Dichelobacter nodosus.
Ceva highlights that Tulaven is the only tulathromycin available in CLAS (Ceva Layered Anti Shatter) vials1, which have less impact on the environment2, are easier to handle3 and transport4, and are preferred by farmers5.
Cuneyt Seckin, Managing Director of Ceva Animal Health, said: “Ceva has been developing its expertise in the treatment of BRD for many years, with a wide range of treatment options and autogenous vaccines available for vets. The launch of Tulaven is the next addition to this range, enabling us to offer even more support to vets and farmers.”
For further information, contact your local Ceva territory manager, call Ceva on 01494 781510 or email cevauk@ceva.com.
References